News Releases

Dec 23, 2020
SHANGHAI and GAITHERSBURG, Md. , Dec. 23, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB ), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced its participation in the following conferences in
Dec 14, 2020
- Global biotech index widely followed and tracked by investors and ETFs - IMAB added to the index upon first annual review since IPO - To be effective prior to the U.S. market open on Monday, December 21, 2020 SHANGHAI and GAITHERSBURG, Md. , Dec. 14, 2020 /PRNewswire/ -- I-Mab (the "Company")
Dec 01, 2020
SHANGHAI and GAITHERSBURG, Md. , Dec. 1, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB ), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today filed a registration statement on Form F-1 with the Securities and
Oct 28, 2020
SHANGHAI, China , and GAITHERSBURG, MD ., Oct. 28, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced its participation in the following conferences
Displaying 1 - 10 of 45